Lobular carcinomas of the breast: cytological diagnostics

Abstract

AIMS: To estimate potentialities of cytological diagnostics of different types of lobular carcinomas of the breast while outpatient examination.

MATERIALS AND METHODS: The data of cytological investigations of 444 patients with carcinoma, which were detected by fine-needle aspiration biopsy, were studied. Traditional cytological diagnostics, as well as the liquid-based technique of preparation of patterns were used, staining of patterns according to the Pappenheim and Papanicolaou methods. A standard protocol for immunocytochemical reactions was used.

RESULTS: Lobular carcinoma was detected in 15 patients. Types of lobular carcinomas were verified by cytological method were retrospectively identified.

Classical, solid and tubular types of lobular carcinoma (n=7,46.7%; n=5,33.3%; n=1,6.7%) differed from unspecified breast carcinomas. In the classical type, vacuoles with a target-like inclusion (probably a drop of mucin) were a significant feature. In the solid type, the absence of complexes with a large number of separately located similar tumor cells was noticed. The tubular type was distinguished by the presence of tubular structures. The liquid-based technique helps to differentiate lobular and unspecified carcinoma using an immunocytochemical reaction with E-cadherin.

CONCLUSION: The results of the study indicate that lobular carcinomas of the breast are 3.4% of all breast carcinomas. Taking into consideration the differences in prognosis, it is important to differentiate between lobular and unspecified ductal carcinoma at the outpatient level of diagnostics, as this is deciding for treatment strategy choice.

Keywords

lobular carcinomas / classical, solid and tubular types / fine-needle aspiration / cytological diagnostics / liquid-based technique of cytological diagnostics

References

[1] Li CI, Anderson BO, Daling JO, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289(11):1421–1424. doi: 10.1001/jama.289.11.1421

[2] Li C.I., Anderson B.O., Daling J.O., Moe R.E. Trends in incidence rates of invasive lobular and ductal breast carcinoma // JAMA. 2003. Vol. 289, N 11. P. 1421–1424. doi: 10.1001/jama.289.11.1421

[3] Li CI, Malone KE, Porter PL, et al. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. JAMA. 2003;289(24):3254–3263. doi: 10.1001/jama.289.24.3254

[4] Li C.I., Malone K.E., Porter P.L., et al. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older // JAMA. 2003. Vol. 289, N 24. P. 3254–3263. doi: 10.1001/jama.289.24.3254

[5] Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histological types of breast carcinoma. Cancer. 2002;95(12):2455–2464. doi: 10.1002/cncr.10984

[6] Daling J.R., Malone K.E., Doody D.R., et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histological types of breast carcinoma // Cancer. 2002. Vol. 95, N 12. P. 2455–2464. doi: 10.1002/cncr.10984

[7] Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(7):593–600.

[8] Newcomb P.A., Titus-Ernstoff L., Egan K.M., et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk // Cancer Epidemiol Biomarkers Prev. 2002. Vol. 11, N 7. P. 593–600.

[9] Breast tumours/edited by WHO Classification of Tumours Editorial Board. Fifth edition. I Lyon: International Agency for Besearch on Cancer; 2019. Р. 303.

[10] Breast tumours/edited by WHO Classification of Tumours Editorial Board. Fifth edition. I Lyon : International Agency for Besearch on Cancer, 2019. Р. 303.

[11] Christgen M, Steinemann D, Kühnle E, et al. Lobular breast cancer: clinical, molecular and morphological characteristics. Pathol Res Pract. 2016;212(7):583–597.

[12] Christgen M., Steinemann D., Kühnle E., et al. Lobular breast cancer: clinical, molecular and morphological characteristics // Pathol Res Pract. 2016. Vol. 212, N 7. P. 583–597.

[13] Pharoah PD, Guilford P, Caldas C, et al. The international gastric cancer linkage consortium incidence of gastric cancer and breast cancer in CDH1 (E-Cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–1353. doi: 10.1053/gast.2001.29611

[14] Pharoah P.D., Guilford P., Caldas C. The international gastric cancer linkage consortium incidence of gastric cancer and breast cancer in CDH1 (E-Cadherin) mutation carriers from hereditary diffuse gastric cancer families // Gastroenterology. 2001. Vol. 121, N 6. P. 1348–1353. doi: 10.1053/gast.2001.29611

[15] Luveta J, Parks RM, Heery DM, et al. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. Oncol Ther. 2020;8(1):1–11. doi: 10.1007/s40487-019-00105-0

[16] Luveta J., Parks R.M., Heery D.M., et al. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy // Oncol Ther. 2020. Vol. 8, N 1. P. 1–11. doi: 10.1007/s40487-019-00105-0

[17] Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77(1):113–120. doi: 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8

[18] Sastre-Garau X., Jouve M., Asselain B., et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns // Cancer. 1996. Vol. 77, N 1. P. 113–120. doi: 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8

[19] Reed AE, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics. Breast Cancer Res. 2015;17(1):12. doi: 10.1186/s13058-015-0519-x

[20] Reed A.E., Kutasovic J.R., Lakhani S.R., Simpson P.T. Invasive lobular carcinoma of the breast: morphology, biomarkers and ‘omics // Breast Cancer Res. 2015. Vol. 17, N 1. P. 12. doi: 10.1186/s13058-015-0519-x

[21] Rakha EA, Gill MS, El-Sayed ME, et al. The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat. 2009;114(2):243–250. doi: 10.1007/s10549-008-0007-4

[22] Rakha E.A., Gill M.S., El-Sayed M.E., et al. The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology // Breast Cancer Res Treat. 2009. Vol. 114, N 2. P. 243–250. doi: 10.1007/s10549-008-0007-4

[23] Dixon JM, Anderson TJ, Page DL, et al. Infiltrating lobular carcinoma of the breast. Histopathology. 1982;6(2):149–161. doi: 10.1111/j.1365-2559.1982.tb02712.x

[24] Dixon J.M., Anderson T.J., Page D.L., et al. Infiltrating lobular carcinoma of the breast // Histopathology. 1982. Vol. 6, N 2. P. 149–161. doi: 10.1111/j.1365-2559.1982.tb02712.x

[25] Wilson N, Ironside A, Diana A, Oikonomidou O. Lobular breast cancer: a review. Front Oncol. 2021;10:591399. doi: 10.3389/fonc.2020.591399

[26] Wilson N., Ironside A., Diana A., Oikonomidou O. Lobular breast cancer: a review // Front Oncol. 2021. Vol. 10. P. 591399. doi: 10.3389/fonc.2020.591399

[27] Luveta J, Parks RM, Heery DM, et al. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. Oncol Ther. 2020;8(1):1–11. doi: 10.1007/s40487-019-00105-0

[28] Luveta J., Parks R.M., Heery D.M., et al. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy // Oncol Ther. 2020. Vol. 8, N 1. P. 1–11. doi: 10.1007/s40487-019-00105-0

[29] Orvieto E, Maiorano E, Bottiglieri L, et al. Clinicopathological characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer. 2008;113(7):1511–1520. doi: 10.1002/cncr.23811

[30] Orvieto E., Maiorano E., Bottiglieri L., et al. Clinicopathological characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution // Cancer. 2008. Vol. 113, N 7. P. 1511–1520. doi: 10.1002/cncr.23811

[31] Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149–R156. doi: 10.1186/bcr767

[32] Arpino G., Bardou V.J., Clark G.M., Elledge R.M. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome // Breast Cancer Res. 2004. Vol. 6, N 3. R149–R156. doi: 10.1186/bcr767

[33] Sledge GW, Chagpar A, Perou C. Collective wisdom: lobular carcinoma of the breast. Am Soc Clin Oncol Educ Book. 2016;35:18–21. doi: 10.1200/EDBK_100002

[34] Sledge G.W., Chagpar A., Perou C. Collective wisdom: lobular carcinoma of the breast // Am Soc Clin Oncol Educ Book. 2016. Vol. 35. P. 18–21. doi: 10.1200/EDBK_100002

[35] Borisova EI, Vyshinskaja GV, Gutorov SL, Stepanchenko MV. Osobennosti klinicheskogo techenija invazivnogo dol’kovogo raka molochnoj zhelezy. Farmateka. 2014;(17):38–42.

[36] Борисова Е.И., Вышинская Г.В., Гуторов С.Л., Степанченко М.В. Особенности клинического течения инвазивного долькового рака молочной железы // Фарматека. 2014. № 17. С. 38–42.

[37] Filonenko DA, Ganshina IP, Kondratyeva OE. Characteristics of metastatic lobular breast cancer. Obstetrics and gynecology. 2019;10:180–187. doi: 10.18565/aig.2019.10.180-187

[38] Филоненко Д.А., Ганьшина И.П., Кондратьева О.Е., и др. Особенности метастазирования долькового рака молочной железы // Акушерство и гинекология. 2019. № 10. С. 180–187. doi: 10.18565/aig.2019.10.180-187

[39] Namikawa T, Hanazaki K. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach. Surg Today. 2014;44(8):1392–1399. doi: 10.1007/s00595-013-0671-9

[40] Namikawa T., Hanazaki K. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach // Surg Today. 2014. Т. 44, № 8. С. 1392–1399. doi: 10.1007/s00595-013-0671-9

[41] Joh JE, Esposito NN, Kiluk JV, et al. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy. Breast J. 2012;18(6):569–574. doi: 10.1111/tbj.12006

[42] Joh J.E., Esposito N.N., Kiluk J.V., et al. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy // Breast J. 2012. Vol. 18, N 6. P. 569–574. doi: 10.1111/tbj.12006

[43] Truin W, Voogd AC, Vreugdenhil G, et al. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol. 2012;23(11):2859–2865. doi: 10.1093/annonc/mds180

[44] Truin W., Voogd A.C., Vreugdenhil G., et al. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer // Ann Oncol. 2012. Vol. 23, N 11. P. 2859–2865. doi: 10.1093/annonc/mds180

[45] Menet E, Becette V, Briffod M. Cytologic diagnosis of lobular carcinoma of the breast experience with 555 patients in the Rene Huguenin Cancer Center. Cancer Cytopathology. 2008;114(2):111–117. doi: 10.1002/cncr.23347

[46] Menet E., Becette V., Briffod M. Cytologic diagnosis of lobular carcinoma of the breast experience with 555 patients in the Rene Huguenin Cancer Center // Cancer Cytopathology. 2008. Vol. 114, N 2. P. 111–117. doi: 10.1002/cncr.23347

[47] Hwang S, Ioffe O, Lee I, et al. Cytologic diagnosis of invasive lobular carcinoma: factors associated with negative and equivocal diagnoses. Diagn Cytopathol. 2004;31(2):87–93. doi: 10.1002/dc.20084

[48] Hwang S., Ioffe O., Lee I., et al. Cytologic diagnosis of invasive lobular carcinoma: factors associated with negative and equivocal diagnoses // Diagn Cytopathol. 2004. Vol. 31, N 2. P. 87–93. doi: 10.1002/dc.20084

[49] Tan SM, Behranwala KA, Trott PA, et al. A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma. Eur J Surg Oncol. 2002;28(3):203–208. doi: 10.1053/ejso.2001.1236

[50] Tan S.M., Behranwala K.A., Trott P.A., et al. A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma // Eur J Surg Oncol. 2002. Vol. 28, N 3. P. 203–208. doi: 10.1053/ejso.2001.1236

[51] McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res. 2021;23(1):6. doi: 10.1186/s13058-020-01384-6

[52] McCart Reed A.E., Kalinowski L., Simpson P.T., Lakhani S.R. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype // Breast Cancer Res. 2021. Vol. 23, N 1. P. 6. doi: 10.1186/s13058-020-01384-6

[53] Mouabbi JA, Hassan A, Lim B, et al. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022;193(2):253–264. doi: 10.1007/s10549-022-06572-w

[54] Mouabbi J.A., Hassan A., Lim B., et al. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer // Breast Cancer Res Treat. 2022. Vol. 193, N 2. P. 253–264. doi: 10.1007/s10549-022-06572-w

[55] Djerroudi L, Cabel L, Bidard FC, Vincent-Salomon A. Invasive lobular carcinoma of the breast: toward tailoring therapy? J Natl Cancer Inst. 2022;114(11):1434–1436. doi: 10.1093/jnci/djac159

[56] Djerroudi L., Cabel L., Bidard F.C., Vincent-Salomon A. Invasive lobular carcinoma of the breast: toward tailoring therapy? // J Natl Cancer Inst. 2022. Vol. 114, N 11. P. 1434–1436. doi: 10.1093/jnci/djac159

RIGHTS & PERMISSIONS

Григорук О.Г., Москвина Т.А., Баулина Л.М., Синкина Т.В., Вихлянов И.В.